We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PacBio's Stock Up on Munster Deal for Male Infertility Research
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases.
Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome’s role in male infertility, and support Germany’s GenomeDE Modellvorhaben project. The results will also benefit the International Male Infertility Genomics Consortium, connecting with eight other countries.
Shares of PACB have gained 31.8% since the announcement on Sept. 4.
Significance of PacBio’s Collaboration
This partnership enhances PacBio’s role in advancing genomics within healthcare by addressing complex genetic challenges, particularly male infertility. The system’s accuracy will provide critical insights into the Y chromosome, which will help uncover the genetic causes of male infertility, providing critical insights that are especially valuable for aging European populations facing declining birth rates and increasing healthcare demands. The collaboration will also strengthen PacBio’s growth in Europe and play a key role in integrating genomic medicine into everyday clinical practice, particularly for rare diseases and cancer.
The University of Munster plans to sequence the genomes of 500 male infertility patients using PacBio’s Revio system within the next year. It will also lead trio sequencing of rare disease families to identify whether genetic disorders are inherited maternally or paternally.
PacBio’s HiFi technology will support research into male infertility at the University of Munster's Center of Medical Genetics. This partnership, part of PacBio’s European growth strategy, aims to advance the center’s research into male infertility, familial cancer and rare diseases, addressing critical healthcare challenges in Germany and beyond. PacBio sees this collaboration as key to fulfilling its mission of leveraging genomics to improve global health outcomes.
Market Prospects Favoring PACB
Per a report in Straits Research, the global genome sequencing market size was worth $41.92 billion in 2023. It is anticipated to reach $101.23 billion by 2032 at a CAGR of 11.7%.
The robust growth is likely to be driven by a rising patient population and increasing demand for flexible bioprocessing. The shift in rare disease diagnosis from symptom-based analysis to genomics, which enables targeted therapies and better care, is also boosting demand.
A Recent Development at PacBio
In May, PacBio was selected alongside Ambry Genetics to support the University of California, Irvine, and the GREGoR Consortium in the Pediatric Mendelian Genomics Research Center program. This NIH-funded initiative will use PacBio's long-read sequencing technology to analyze up to 7,000 genomes over three years, aiming to uncover the genetic causes of rare diseases that previous genomic analysis could not identify.
PACB Stock Price Performance
Shares of PacBio have plunged 82.3% year to date against the industry’s 15.7% growth. The S&P 500 has witnessed a 14.4% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, PacBio carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and Aveanna Healthcare (AVAH - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and Aveanna Healthcare carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have risen 3.7% year to date compared with the industry’s 10.2% growth.
Aveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.
AVAH's shares have risen 104.5% year to date compared with the industry’s 15.7% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PacBio's Stock Up on Munster Deal for Male Infertility Research
Pacific Biosciences of California, Inc. (PACB - Free Report) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases.
Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome’s role in male infertility, and support Germany’s GenomeDE Modellvorhaben project. The results will also benefit the International Male Infertility Genomics Consortium, connecting with eight other countries.
Shares of PACB have gained 31.8% since the announcement on Sept. 4.
Significance of PacBio’s Collaboration
This partnership enhances PacBio’s role in advancing genomics within healthcare by addressing complex genetic challenges, particularly male infertility. The system’s accuracy will provide critical insights into the Y chromosome, which will help uncover the genetic causes of male infertility, providing critical insights that are especially valuable for aging European populations facing declining birth rates and increasing healthcare demands. The collaboration will also strengthen PacBio’s growth in Europe and play a key role in integrating genomic medicine into everyday clinical practice, particularly for rare diseases and cancer.
The University of Munster plans to sequence the genomes of 500 male infertility patients using PacBio’s Revio system within the next year. It will also lead trio sequencing of rare disease families to identify whether genetic disorders are inherited maternally or paternally.
PacBio’s HiFi technology will support research into male infertility at the University of Munster's Center of Medical Genetics. This partnership, part of PacBio’s European growth strategy, aims to advance the center’s research into male infertility, familial cancer and rare diseases, addressing critical healthcare challenges in Germany and beyond. PacBio sees this collaboration as key to fulfilling its mission of leveraging genomics to improve global health outcomes.
Market Prospects Favoring PACB
Per a report in Straits Research, the global genome sequencing market size was worth $41.92 billion in 2023. It is anticipated to reach $101.23 billion by 2032 at a CAGR of 11.7%.
The robust growth is likely to be driven by a rising patient population and increasing demand for flexible bioprocessing. The shift in rare disease diagnosis from symptom-based analysis to genomics, which enables targeted therapies and better care, is also boosting demand.
A Recent Development at PacBio
In May, PacBio was selected alongside Ambry Genetics to support the University of California, Irvine, and the GREGoR Consortium in the Pediatric Mendelian Genomics Research Center program. This NIH-funded initiative will use PacBio's long-read sequencing technology to analyze up to 7,000 genomes over three years, aiming to uncover the genetic causes of rare diseases that previous genomic analysis could not identify.
PACB Stock Price Performance
Shares of PacBio have plunged 82.3% year to date against the industry’s 15.7% growth. The S&P 500 has witnessed a 14.4% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, PacBio carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are Universal Health Services (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and Aveanna Healthcare (AVAH - Free Report) . While Universal Health Services sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and Aveanna Healthcare carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Services has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry's 34.8% growth year to date.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have risen 3.7% year to date compared with the industry’s 10.2% growth.
Aveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.
AVAH's shares have risen 104.5% year to date compared with the industry’s 15.7% growth.